Open

Lung Cancer Treatment Study

In this study, we want to see if a new type of medicine for lung cancer treatment is better than the usual treatments. We are curious if this new medicine could improve things for people with lung cancer. This will help us understand if the new medicine will treat people better or faster.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

At each visit, you will meet with a provider of the study team to do lab testing and get medicine. You will take either the study drug or a placebo pill twice a day, every day. CT scans will be done every 6 weeks. The study also involves blood draws and questionnaires to answer.

Total length of participation:
2-4 years

Looking for Specific Volunteers

Able to participate:

You have Stage III or Stage IV Lung Cancer
You have a KRAS G12C Mutation
You have not yet received treatment for your cancer diagnosis
You are willing to take the study medication or a placebo twice daily by swallowing capsules

Not eligible if:

You have Small Cell Lung Cancer
You have other mutations besides KRAS G12C
You are being treated for another type of cancer or have been in the past 2 years

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Becky Clinard
CancCtrOncologyClinicalResearch@unchealth.unc.edu
(919) 784-2500

Primary Visit Location

UNC Rex Cancer Center
2901 Blue Ridge Rd, Raleigh, NC 27607, USA

Secondary Contact

Anderson Black

Secondary Visit Location

Rex Cancer Center of Wakefield
11200 Governor Manly Way Raleigh NC 27614

Additional Study Information

Principal Investigator

Brendan McNulty
UNC Hospitals - Rex

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung)

IRB Number

24-0796

ClinicalTrials.gov

NCT06119581

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.